Inspirion Wealth Advisors LLC Increases Holdings in Johnson & Johnson (NYSE:JNJ)

Inspirion Wealth Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 5.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,664 shares of the company’s stock after buying an additional 85 shares during the quarter. Inspirion Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $243,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Boit C F David raised its holdings in Johnson & Johnson by 3.7% in the fourth quarter. Boit C F David now owns 41,625 shares of the company’s stock worth $6,700,000 after purchasing an additional 1,500 shares in the last quarter. Prime Capital Investment Advisors LLC lifted its position in Johnson & Johnson by 53.0% during the 4th quarter. Prime Capital Investment Advisors LLC now owns 235,357 shares of the company’s stock valued at $36,890,000 after acquiring an additional 81,504 shares during the period. Cranbrook Wealth Management LLC boosted its stake in Johnson & Johnson by 4.4% during the fourth quarter. Cranbrook Wealth Management LLC now owns 1,886 shares of the company’s stock worth $296,000 after acquiring an additional 80 shares in the last quarter. QV Investors Inc. grew its holdings in Johnson & Johnson by 40.9% in the fourth quarter. QV Investors Inc. now owns 99,750 shares of the company’s stock worth $15,635,000 after purchasing an additional 28,960 shares during the period. Finally, Grimes & Company Inc. increased its stake in shares of Johnson & Johnson by 2.7% during the fourth quarter. Grimes & Company Inc. now owns 95,715 shares of the company’s stock valued at $15,002,000 after purchasing an additional 2,544 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on JNJ. TD Cowen reduced their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday. TD Securities dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Finally, HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Price Performance

Shares of JNJ traded up $0.40 during midday trading on Friday, hitting $160.62. 4,579,186 shares of the company traded hands, compared to its average volume of 7,354,407. The stock has a market cap of $386.56 billion, a price-to-earnings ratio of 10.01, a PEG ratio of 2.63 and a beta of 0.52. The firm has a 50 day moving average of $151.17 and a 200-day moving average of $153.10. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm’s revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.80 earnings per share. On average, analysts forecast that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.09%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.